Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.

Autor: Hell S; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Jentzsch M; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Franke GN; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Jäkel N; Department of Hematology/Oncology, University Hospital Halle, Halle (Saale), Germany., Schulze S; Krukenberg Cancer Center, University Halle, Halle (Saale), Germany., Edelmann J; Leipzig Medical Center, Institute of Legal Medicine, University Leipzig, Leipzig, Germany., Nenoff K; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Grieb N; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Jeremic V; Department for Operations Research and Statistics, Faculty of Organizational Sciences, University of Belgrade, Belgrade, Serbia., Cross M; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Leiblein S; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Bach E; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Pönisch W; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Al-Ali HK; Krukenberg Cancer Center, University Halle, Halle (Saale), Germany., Schwind S; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Platzbecker U; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Lange T; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Niederwieser D; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany., Vucinic V; Leipzig Medical Center, Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University Leipzig, Leipzig, Germany. vladan.vucinic@medizin.uni-leipzig.de.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2022 May; Vol. 57 (5), pp. 824-826. Date of Electronic Publication: 2022 Feb 18.
DOI: 10.1038/s41409-022-01609-6
Databáze: MEDLINE